Clinical Trials Logo

Clinical Trial Summary

An estimated 8% to 15% of patients hospitalized for a coronary pathology undergo coronary revascularization surgery with extracorporeal circulation (ECC). (1) Like most major cardiac surgical interventions, it is performed with the heart stopped; this leads to more or less severe myocardial ischemia. The heart is stopped (and therefore deprived of oxygen) for a duration that varies depending on the number of bypasses required, and on the local difficulties encountered. On average, myocardial ischemia lasts between 20 and 80 minutes. Heart protection during coronary revascularization surgery remains a crucial factor in limiting the heart's aerobic function during aortic clamping, and in minimizing the resulting post-operatory ventricular dysfunction. Its quality is a determining factor of the post-operatory issue.

High-performance heart protection solutions such as Custodiol have been used by heart surgeons for a few years. They are used as an alternative choice to other cardioplegic solutions, the efficacy of which has already been proven (St Thomas). These two myocardial protection solutions have never been evaluated in an in vivo, randomized, comparative trial.


Clinical Trial Description

Myocardial microdialysis is the state-of-the-art technique for evaluating the protective effects of cardioplegic solutions; it enables physicians to monitor oxidation-reduction muscle metabolism during an ongoing operation. ;


Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention


Related Conditions & MeSH terms


NCT number NCT01401140
Study type Interventional
Source Centre Hospitalier Universitaire de Saint Etienne
Contact
Status Completed
Phase Phase 3
Start date June 2010
Completion date March 2012

See also
  Status Clinical Trial Phase
Recruiting NCT05133843 - Complete Functional Assessment of Intermediate Coronary Artery Stenosis Before and After Transcatheter Aortic Valve Implantation (TAVI) in Patients With Severe Symptomatic Aortic Valve Stenosis N/A
Completed NCT01205776 - EXCEL Clinical Trial N/A
Completed NCT01182428 - XIENCE V: SPIRIT WOMEN Sub-study Phase 4
Completed NCT00739466 - Biorest Liposomal Alendronate With Stenting sTudy (BLAST) Phase 2
Completed NCT01332591 - Multivessel Disease Diagnosed at the Time of PPCI for STEMI: Complete Revascularization Versus Conservative Strategy. N/A
Completed NCT01310309 - EXecutive Registry: Evaluating XIENCE V® in a Multi Vessel Disease Phase 4
Completed NCT00531011 - EXecutive RCT: Evaluating XIENCE V® in a Multi Vessel Disease Phase 4
Not yet recruiting NCT06052670 - Functional Diagnostic Accuracy of Ultrasonic Flow Ratio in Assessment of Coronary Artery Lesions
Completed NCT05509296 - Compare the Effectiveness and Safety of Two Different Kinds of Cutting Balloon in Coronary Artery Disease N/A
Not yet recruiting NCT05393882 - Impact of Cholesterol Level on Long-term Coronary Bypass Graft Patency
Recruiting NCT06397820 - Relation Between AI-QCA and Cardiac PET
Active, not recruiting NCT01960504 - First in Man Study of the DREAMS 2nd Generation Drug Eluting Absorbable Metal Scaffold (BIOSOLVE-II) N/A
Completed NCT01721096 - XIENCE PRIME Japan Post-Marketing Surveillance (PMS)
Active, not recruiting NCT01342822 - Trial to Assess the Everolimus-Eluting Coronary Stent System (PROMUS Element) for Coronary Revascularization Phase 4
Completed NCT01205789 - EXCEL Clinical Trial (Universal Registry) N/A
Recruiting NCT05532605 - Effects of Mindfulness Based Therapy on Illness and Depression in Cardiac Rehab Phase-i N/A
Completed NCT02066623 - Observational Study to Evaluate Short and Long-term Safety of the ABSORB Scaffold
Not yet recruiting NCT02946320 - Optimal Predilatation Technique for BVS Implantation Phase 3
Terminated NCT01136915 - Kidney Damage In Patients With Severe Fall In eGFR Phase 4
Completed NCT01136876 - Kidney Damage in Patients With Moderate Fall in eGFR Phase 4